Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6871 to 6885 of 8905 results

  1. Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]

    Discontinued Reference number: GID-TA10933

    Technology appraisal guidance
    Discontinued

  2. Pralsetinib for thyroid cancer [ID4018]

    Discontinued Reference number: GID-TA10910

    Technology appraisal guidance
    Discontinued

  3. Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]

    Discontinued Reference number: GID-TA11033

    Technology appraisal guidance
    Discontinued

  4. Mavacamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6523]

    In development Reference number: GID-TA11664 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]

    Discontinued Reference number: GID-TA11338

    Technology appraisal guidance
    Discontinued

  6. Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]

    In development Reference number: GID-TA11365 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086]

    In development Reference number: GID-TA11709 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147]

    In development Reference number: GID-TA11689 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over TSID 12091

    In development Reference number: GID-TA11679 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632

    In development Reference number: GID-TA11631 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]

    In development Reference number: GID-TA11523 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]

    In development Reference number: GID-TA11455 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene for babies 6 months and over to children under 2 years TS ID 11774

    Discontinued Reference number: GID-TA11124

    Technology appraisal guidance
    Discontinued

  14. Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]

    In development Reference number: GID-TA10826 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]

    In development Reference number: GID-TA10779 Expected publication date: TBC

    Technology appraisal guidance
    In development